Growth Has Never Been More Imminent For CRONOS GROUP INC (OTCMKTS:PRMCF)

There has been an upward trend in the share price of CRONOS GROUP INC (OTCMKTS:PRMCF).The company which has been trending upwards since our last analysis, which can be obtained here, has jumped from lows of $2.5 to highs of $3.5 during a one month period finally closing at $3 yesterday.The trend described above can be seen below: PRMCF Daily ChartThe company has been on a growth trajectory before, during and after our last analysis. The moves they had made till then were quite remarkable and those made in the current quarter are even better.Currently, the company is on an expansionary strategy where it is investing significant resources in its entry into other parts of the world. Their ability to venture abroad presents them with significant growth capabilities and given that their management as well as competitors have realized this, their strategy has been tied to them getting into the global space.Over the course of this piece, therefore, we will assess how the company has been doing since our last analysis, what new thing they have incorporated into their business model and how this is expected to affect their value creation going into the future.Before this, however, let’s have a brief overview of the company for the sake of first time readers.A Look Into PRMCFCronos Group, founded in 2012, is a geographically diversified and vertically integrated cannabis company. The company operates two wholly-owned Licensed Producers ("LPs") regulated within Health Canada's Access to Cannabis for Medical Purposes Regulations and holds a portfolio of minority investments in other Licensed Producers.They have two flagship subsidiaries: LPs, Peace Naturals Project Inc and Original BC Ltd which are collectively situated on over 125 acres of agricultural, licensed land.Their main focus has always been a building an international iconic brand portfolio and creating value for their shareholders through provision of personalized healthcare for their patients and clients through medical cannabis.This focus hasn’t deviated since inception and isn’t about to deviate now. On the contrary, they have just stepped it up a notch.Strategic Moves MadeIn our last review of PRMCF, we focused on how some of the deals they had made would be beneficial to them going forward.One of those deals was the Pohl-Boskamp strategic partnership, a partnership which would allow would allow them to venture into the European markets through Germany as a strategic front.Pohl-Boskamp owns at least 12,000 pharmacies across Germany alone and operates in over 45 countries globally.The company was meant to enable them begin their trade with Germany, which currently approves of legalization of marijuana, as they work towards delivering the product to other European countries with its legalization in those countries (countries such as Denmark).This venture was mainly for their link to European countries. They were not done yet.In yet another deal, they have entered a strategic joint venture (Cronos Israel) with Kibbutz Gan Shmuel firm in Israel.The deal, which was approved by TSX Venture Exchange on 9^th November, allows the company to utilize the resources that are available in Israel. Such resources include over 4,939 acres of land which can produce up to 100,000 kilograms of cannabis per annum.Given the increased demand for cannabis globally and the proximity of Israel to Germany and other European nations, the move serves the interests of Cronos Inc as much as it does the needs of their market. This seeks to ensure that PRMCF is constantly meeting the demand globally thus constantly making revenues and profits into the future.The output from this project, has been detailed above, will go to European countries especially now that the acceptance of marijuana is increasing very day throughout the globe. With countries such as Denmark expected to legalize recreational marijuana over year 2018, there is a lot that PRMCF could benefit from going forward.The above is further reiterated by the CEO of Cronos, Mike Gorenstein who said:

"I am excited to welcome these key team members to the Cronos Group. Their experience and insight will be valuable assets as we continue to execute on our global strategic initiatives."

Source:FinancialsThe company announced during this quarter that they had just closed a deal, earlier announced, to offer over 5.4 million shares at $3.15: a total of $17.2 million. The deal which was meant to provide the company with necessary cash to finance their working capital as well as expansionary programme was announced to be a success for PRMCF.This was in addition to the fact that their revenues were up 25% from $514,000 in 1Q2017 to $643,000 in 2Q17 and gains on investments stood at $1.3 million over the same quarter.They further made a net profit of $174,879.With the above fundamental expected to grow positively, the company seems to further be in an upward trend and not coming down any soon.We therefore believe that the current price surge is warranted and that PRMCF is on the right path: headed further upwards.ConclusionPRMCF represents one of the success stories in the market. The entity has been on a growth trajectory and is expected to grow further into the future. Nothing will stop a further price surge from taking place for them.We will be updating our subscribers as soon as we know more. For the latest updates on PRMCF, sign up below!Disclosure: We have no position in PRMCF and have not been compensated for this article.